PDX model details
| PDX ID |
272R |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Renal |
Current Generation (* indicates number of generations grown in Castrate host) |
11 |
| Average PDX Generation Time (days +/- SEM) |
189 ± 32 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
272R |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
Y |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 272R |
MSH2 |
-11.1116 |
0.000903868 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 272R |
CDKN1B |
-1.01536 |
0.98941 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 272R |
MSH2 |
-1.01119 |
0.992274 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 272R |
MYC |
0.811972 |
3.51122 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 272R |
CHD7 |
1.02403 |
4.06718 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 272R |
MYC |
1.02403 |
4.06718 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
Clinical Information
| Sample Number |
272R |
| Sample Site |
Prostate |
| Sample source |
Radical prostatectomy |
| Pathology Tumour Diagnosis |
Adenocarcinoma |
| Gleason Score |
9 |
| Primary Gleason Score |
4 |
| Secondary Gleason Score |
5 |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
5 |
| Tumour Grade |
pT3bN1 |
| D'Amico Risk Classification |
7 |
| Tumour Volume (in cc) |
20.2 |
| Treatment Prior to Specimen Collection |
None |
| |
|
Patient Information
| Patient Number |
272 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
9.2 |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Depth
|
ALT_FREQ
|
Consequence
|
Exon
|
GnomAD_AF
|
CADD_PHRED
|
Clinvar_clnsig
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 272R |
BCORL1 |
592 |
0.94 |
frameshift_variant |
'12/12 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
DMD |
106 |
0.91 |
frameshift_variant |
'40/79 |
. |
34 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
BAX |
171 |
0.8 |
frameshift_variant |
'3/5 |
0.0001061 |
23.8 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
PRKDC |
725 |
0.69 |
missense_variant |
'29/87 |
. |
26.6 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
NKX3-1 |
2365 |
0.67 |
inframe_deletion |
'2/2 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
LTBP4 |
243 |
0.56 |
missense_variant |
'11/34 |
0.0001098 |
28 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
MET |
455 |
0.53 |
stop_gained |
'21/21 |
1.22E-05 |
38 |
Uncertain_significance
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
RNF43 |
1135 |
0.52 |
frameshift_variant |
'8/9 |
0 |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
WNT4 |
1047 |
0.51 |
missense_variant |
'2/5 |
. |
33 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
SOX9 |
641 |
0.51 |
missense_variant |
'3/3 |
. |
27.1 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
SMAD2 |
361 |
0.51 |
frameshift_variant |
'11/11 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
CYP2D6 |
411 |
0.5 |
missense_variant |
'2/9 |
1.59E-05 |
29.1 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
OGDH |
399 |
0.5 |
missense_variant |
'7/23 |
. |
33 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
RXRG |
303 |
0.5 |
missense_variant |
'3/10 |
4.48E-05 |
25.9 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
LRP2 |
297 |
0.5 |
missense_variant |
'46/79 |
. |
24.2 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
NOTCH3 |
206 |
0.49 |
missense_variant |
'33/33 |
1.24E-05 |
29.1 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
MTOR |
399 |
0.49 |
missense_variant |
'42/58 |
. |
29.8 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
FANCA |
995 |
0.48 |
missense_variant |
'26/43 |
8.22E-06 |
23.2 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
FGFR4 |
1026 |
0.48 |
missense_variant |
'16/18 |
. |
29.1 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
TRIM33 |
667 |
0.48 |
missense_variant |
'11/20 |
3.66E-05 |
27 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
SPEN |
1306 |
0.48 |
frameshift_variant |
'11/15 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
CACNA1H |
218 |
0.47 |
missense_variant |
'32/35 |
1.79E-05 |
25.5 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
PDGFRB |
855 |
0.47 |
missense_variant |
'13/23 |
4.18E-06 |
24.8 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
PBRM1 |
129 |
0.47 |
frameshift_variant |
'9/30 |
0 |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
ZFHX3 |
1259 |
0.46 |
frameshift_variant |
'9/10 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
CAPN1 |
263 |
0.46 |
missense_variant |
'17/21 |
4.47E-05 |
32 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
CAPN1 |
263 |
0.46 |
missense_variant |
'17/21 |
4.47E-05 |
32 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
AKT3 |
345 |
0.44 |
missense_variant |
'14/14 |
. |
32 |
Pathogenic/Likely_pathogenic
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
ZFHX3 |
1265 |
0.43 |
frameshift_variant |
'9/10 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
CACNA1H |
175 |
0.42 |
missense_variant |
'9/35 |
2.76E-05 |
22.9 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 272R |
ABL1 |
1551 |
0.34 |
missense_variant |
'11/11 |
1.63E-05 |
29.8 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
No information in Drug dosing Table